Anbio Biotechnology Class A Ordinary Shares (NNNN)

FairStock Score: 35/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am looking at Anbio Biotechnology through a Graham-and-Buffett lens, and the first thing I notice is how little record there is. The company makes in vitro diagnostics — lateral flow, fluorescence, PCR, and SARS-CoV-2 rapid tests — for over-the-counter, point-of-care, and laboratory channels. That is a useful niche, but with only 27 employees and no revenue or profit growth data provided, I cannot judge whether it has a durable competitive moat. The only Lynch category available is none, because FairStock says there are only 0 years of filed annual results and it needs three. On the numbers I do have, the business looks profitable but not cheap. At the 2026-10-13 close of $4.26, FairStock calculates a P/E of 28.40 and P/B of 6.17. The provided EPS is $0.15, though no fiscal period is named, so I cannot treat it as a filed-period result. ROE of 27.05% and ROCE of 14.66% are respectable, but the Graham Number of $1.53 implies a margin of safety of -178.43%, meaning the price is far above Graham's conservative value. A Piotroski F-Score of 2/9 is weak, and the Altman Z-score of 8,413.65 is so extreme that I would not rely on it as normal evidence of safety. The $1.2B market cap on a 27-person operation implies enormous expectations. With a 52-week range of $3.88 to $44.73 and a FairStock score of 35/100, I see speculation, not a margin of safety. I would need filed multi-year revenue, profit, and cash flow before calling this a business I understand.

In plain English: Anbio Biotechnology makes medical test kits and diagnostic testing products, including rapid COVID-19 tests, for clinics, labs, and over-the-counter use. The business shows some profit and a high return on shareholders' money, but it has almost no filed annual history and weak financial-quality signs. At $4.26 a share, the price looks expensive compared with the company's profits and net assets, and the stock has swung widely over the past year.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer